Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sernova Corp
(TSV:
SVA
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EDT, Jun 1, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
1.550 (51)
Ask (Size)
1.610 (5)
Prev. Close
1.570
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
May 26, 2022
Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited...
Via
Benzinga
SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
May 06, 2022
From
Sinovac Biotech Ltd.
Via
Business Wire
Performance
More News
Read More
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
April 29, 2022
From
Sinovac Biotech Ltd.
Via
Business Wire
Sinovac Amends Shareholder Rights Plan
February 22, 2022
From
Sinovac Biotech Ltd.
Via
Business Wire
HFCAA News: 128 Chinese Stocks the SEC Could Delist
May 05, 2022
Via
InvestorPlace
New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report
January 26, 2022
Via
Benzinga
Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
January 24, 2022
Via
Benzinga
Sinovac's COVID-19 Vaccine With Pfizer Booster Less Effective Against Omicron: Reuters
January 03, 2022
Via
Benzinga
SINOVAC Reports Unaudited First Half of 2021 Financial Results
December 30, 2021
From
Sinovac Biotech Ltd.
Via
Business Wire
Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
December 09, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
SINOVAC Beijing Settled Litigation of Its Business License and Seals
December 03, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
November 09, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
Sinovac's COVID-19 Vaccine Shows Efficacy, But Lags Rivals In Malaysian Study: Reuters
September 24, 2021
Via
Benzinga
Exposures
COVID-19
Week In Review: Sanofi Acquires Kadmon, A US-China Pharma, For $1.9 Billion
September 11, 2021
Via
Talk Markets
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
September 09, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
September 08, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
Via
Benzinga
Exposures
COVID-19
Inovio To Start Global Late-Stage COVID-19 Vaccine Trial
August 26, 2021
Via
Benzinga
Exposures
COVID-19
SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
August 10, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine
July 20, 2021
Via
Benzinga
Exposures
COVID-19
SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
July 19, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
Lancet Study Shows BioNTech COVID-19 Vaccine Generates 10X Higher Antibody Levels Compared to Sinovac Shot
July 16, 2021
Via
Benzinga
Exposures
COVID-19
SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX
July 12, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old
June 30, 2021
From
Sinovac Biotech Ltd.
Via
Business Wire
World Health Organization Authorizes SINOVAC’s CoronaVac® for Emergency Use
June 02, 2021
From
SINOVAC Biotech Ltd.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.